Lupus & Connective Tissue Diseases
From the Journals
IgA vasculitis increases risks for hypertension, chronic kidney disease
Data “suggest that IgAV should not be considered a ‘single-hit’ disease.”
Conference Coverage
RELIEF: In Behçet’s, apremilast improves oral ulcers for up to 28 weeks
Apremilast was safe and effective for treating oral ulcers in patients with Behçet’s disease in a phase 3 study
Conference Coverage
Three drugs disappoint in SSc trials, but show some promise
CHICAGO – Recent randomized, placebo-controlled, phase 3 trials of tocilizumab, abatacept, and riociguat for the...
Feature
ACR CRISS: A way forward for scleroderma treatment trials?
Conference Coverage
FDA urged to bring rheumatologists into gadolinium safety discussion
Conference Coverage
Montreal Cognitive Assessment fares well for rapid, reliable screening in SLE
CHICAGO – The Montreal Cognitive Assessment Test offers major advantages over a formal neuropsychological test battery.
From the Journals
Short-term lung function better predicts mortality risk in SSc
Surrogate measures of lung disease progression may help to determine the need for early intervention.
Conference Coverage
High incidence of treatment-resistant hypertension in SLE comes with high mortality
CHICAGO – Treatment-resistant hypertension is associated with a 289% increased all-cause mortality risk in systemic lupus erythematosus.
Conference Coverage
Development of reversible B-cell inhibitor XmAb5871 for SLE moves forward
From the Journals
Careful follow-up is key in lupus psychosis
Treatment can lead to good outcomes for most patients with careful follow-up, according to a large international study.
Conference Coverage
Fear of blindness hobbles hydroxychloroquine treatment of SLE